841 IMPROVED OUTCOME FOR POOR-PROGNOSIS METASTATIC GERM CELL CANCER: A SINGLE CENTER EXPERIENCE IN JAPAN
Lists
Only you see this
Abstract
You have accessJournal of UrologyPenis/Testis/Urethra: Benign & Malignant Disease III1 Apr 2010841 IMPROVED OUTCOME FOR POOR-PROGNOSIS METASTATIC GERM CELL CANCER: A SINGLE CENTER EXPERIENCE IN JAPAN Shigeyuki Yamada, Hideo Saito, Yasuhiro Kaiho, Akihiro Ito, Shigeto Ishidoya, and Yoichi Arai Shigeyuki YamadaShigeyuki Yamada More articles by this author , Hideo SaitoHideo Saito More articles by this author , Yasuhiro KaihoYasuhiro Kaiho More articles by this author , Akihiro ItoAkihiro Ito More articles by this author , Shigeto IshidoyaShigeto Ishidoya More articles by this author , and Yoichi AraiYoichi Arai More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.2343AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The International Germ Cell Consensus (IGCC) classification has identified three prognostic groups of patients with metastatic germ cell cancer. ‘Poor prognosis' is based on primary tumor localization, presence of non-pulmonary visceral metastases, and/or high serum tumor marker levels. The 5-year overall survival rate of these patients is reportedly 48%. However, treatment outcomes have improved among those treated in or after 1990 and 5-year overall survival has increased to 71%. The present study aimed to evaluate treatment outcomes for a single institution in Japan, and to identify prognostic factors for ‘IGCC poor-prognosis' germ cell cancer. METHODS We retrospectively analyzed 341 germ cell cancer patients treated at Tohoku University Hospital between May 1979 and December 2007. Of these, 163 patients showed metastatic disease at initial diagnosis. Fifty-four patients were classified as the poor prognosis group by IGCC classifications. RESULTS Median age at diagnosis was 29.5 years. Twenty-five patients (46%) showed non-pulmonary visceral metastasis and 38 patients (70%) displayed extremely elevated serum tumor marker level (S3). Median follow-up period for all patients was 32 months. Median number of chemotherapy treatment cycles was 18. Five-year overall survival was 68%. Twenty-one patients (38%) treated with cisplatin/etoposide-based chemotherapy showed significantly better 5-year overall survival (88.4%). On multivariate analysis, the kind of induction chemotherapy regimen was an independent predictor of overall survival. CONCLUSIONS A trend toward increased survival was seen for ‘IGCC poor-prognosis' germ cell cancer, with a particularly large increase in survival for patients treated with cisplatin/etoposide-based chemotherapies. This increase is most likely attributable to both more effective chemotherapy regimens and more extensive care in experienced institutes. Sendai, Japan© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e328-e329 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shigeyuki Yamada More articles by this author Hideo Saito More articles by this author Yasuhiro Kaiho More articles by this author Akihiro Ito More articles by this author Shigeto Ishidoya More articles by this author Yoichi Arai More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
BibTeX
@article{yamada2010improved,
author = {Shigeyuki Yamada and Hideo Saitô and Yasuhiro Kaiho and Akihiro Ito and Shigeto Ishidoya and Yoichi Arai},
title = {{841 IMPROVED OUTCOME FOR POOR-PROGNOSIS METASTATIC GERM CELL CANCER: A SINGLE CENTER EXPERIENCE IN JAPAN}},
journal = {The Journal of Urology},
year = {2010},
doi = {10.1016/j.juro.2010.02.2343},
}Loading related content...